secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0000950170-24-120289
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus presents pre-clinical data for obesity drug CRB-913; Phase 1 start Q1 2025
--------------------------------------------------------------------------------

- CRB-913 showed 15-fold lower brain levels vs monlunabant in mice; plasma-to-brain ratio 10x better than monlunabant.
- Weight loss up to 38% in DIO mice at 80 mg/kg/day over 28 days; no plateau at doses up to 80 mg/kg/day.
- Switching from semaglutide to CRB-913 maintained weight loss post-withdrawal, with doubling of fat reduction vs semaglutide alone.
- Human-equivalent doses range from 30 mg/day to 450 mg/day based on allometric scaling.
- IND-enabling studies ongoing; first patient in Phase 1 expected in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024120289/0000950170-24-120289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024120289/crbp-20241104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-120289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer